Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia

Critical Care Medicine

Volumn 32, Issue 5, 2004, Pages 1136-1140

  Derhaschnig, Ulla ^a   Bergmair, Doris ^a   Marsik, Claudia ^a   Schlifke, Irene ^a   Wijdenes, John ^b   Jilma, Bernd ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Diaclone   (France)

Author keywords

Blocking antibody; Coagulation; Endotoxemia; Interleukin 6; Randomized clinical trial

Indexed keywords

ANTIPLASMIN; BACTERIUM LIPOPOLYSACCHARIDE; C REACTIVE PROTEIN; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTOXIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B E8; PLACEBO; PLASMIN; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; BIOASSAY; BLOOD CLOTTING; BLOOD SAMPLING; BOLUS INJECTION; CANCER CELL CULTURE; CELL ACTIVATION; CELL ASSAY; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENDOTOXEMIA; FIBRINOLYSIS; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; INFLAMMATION; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TRANSCRIPTION REGULATION;

ADULT; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION DISORDERS; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; E-SELECTIN; ENDOTOXEMIA; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; POLYMERASE CHAIN REACTION; THROMBOPLASTIN; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2442498480     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000126265.08175.BE     Document Type: Article

References (41)

1. Friedman G, Silva E, Vincent JL: Has the mortality of septic shock changed with time? Crit Care Med 1998; 26:2078-2086
2. Esmon CT: Role of coagulation inhibitors in inflammation. Thromb Haemost 2001; 86: 51-56
3. Martin C, Boisson C, Haccoun M, et al: Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 1997; 25:1813-1819
4. Reinhart K, Bayer O, Brunkhorst F, et al: Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002; 30:S302-S312
5. Pallua N, Low JF, von Heimburg D: Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model. Crit Care Med 2003; 31:1495-1501
6. Neumann FJ, Ott I, Marx N, et al: Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997; 17: 3399-3405
7. Kerr R, Stirling D, Ludlam CA: Interleukin 6 and haemostasis. Br J Haematol 2001; 115:3-12
8. Stouthard JM, Levi M, Hack CE, et al: Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76:738-742
9. van der Poll T, Levi M, Hack CE, et al: Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 1253-1259
10. Suffredini AF, Hochstein HD, McMahon FG: Dose-related inflammatory effects of intravenous endotoxin in humans: Evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis 1999; 179:1278-1282
11. Levi M, van der Poll T, ten Cate H, et al: The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997; 27:3-9
12. de Jonge E, Dekkers PE, Creasey AA, et al: Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95:1124-1129
13. Racadot E, Audhuy B, Duvernoy H, et al: Clinical and immunological follow-up of patients with AIDS-associated Kaposi's sarcoma treated with an anti-IL-6 monoclonal antibody. Cytokines Mol Ther 1995; 1:133-138
14. Bataille R, Barlogie B, Lu ZY, et al: Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86:685-691
15. Beck JT, Hsu SM, Wijdenes J, et al: Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330:602-605
16. Emilie D, Wijdenes J, Gisselbrecht C, et al: Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: Effect on lymphoma growth and on B clinical symptoms. Blood 1994; 84:2472-2479
17. Wendling D, Racadot E, Wijdenes J: Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993; 20:259-262
18. Klein B, Wijdenes J, Zhang XG, et al: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78:1198-1204
19. Moreau P, Harousseau JL, Wijdenes J, et al: A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol 2000; 109:661-664
20. Blay JY, Rossi JF, Wijdenes J, et al: Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997; 72:424-430
21. Haddad E, Paczesny S, Leblond V, et al: Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1-2 clinical trial. Blood 2001; 97:1590-1597
22. Legouffe E, Liautard J, Gaillard JP, et al: Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immunol 1994; 98: 323-329
23. Wijdenes J, Racadot E, Wendling D: Interleukin-6 antibodies in rheumatoid arthritis. J Interferon Res 1994; 14:297-298
24. Bataille R, Klein B: C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum 1992; 35:982-984
25. Hollenstein U, Homoncik M, Knobl P, et al: Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans. Clin Pharmacol Ther 2002; 71:368-374
26. Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, et al: Evaluation of antiinflammatory and antiadhesive effects of heparin in human endotoxemia. Crit Care Med 2003; 31:1108-1112
27. Jilma B, Marsik C, Mayr F, et al: Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther 2002; 72:403-410
28. Derhaschnig U, Reiter R, Knobl P, et al: Recombinant human activated protein C (rhAPC, drotrecogin alfa activated) has minimal effect on markers of coagulation, fibrinolysis and inflammation in acute human endotoxemia. Blood 2003; 102:2093-2098
29. Jilma B, Blann A, Pernerstorfer T, et al: Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 1999; 159:857-863
30. Klouche M, Bhakdi S, Hemmes M, et al: Novel path to activation of vascular smooth muscle cells: Up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol 1999; 163: 4583-4589
31. Stolley PD, Strom BL: Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 1986; 39:489-490
32. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990; 265:621-636
33. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-454
34. Weinhold B, Bader A, Poli V, et al. Interleukin-6 is necessary, but not sufficient, for induction of the human C-reactive protein gene in vivo. Biochem J 1997; 325:617-621
35. Abraham E, Reinhart K, Svoboda P, et al: Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29:2081-2089
36. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose anti-thrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878
37. Mackman N: Regulation of the tissue factor gene. Thromb Haemost 1997; 78:747-754
38. van der Poll T, Levi M, van Deventer SJ, et al: Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 1994; 63:446-451
39. Pajkrt D, van der Poll T, Levi M, et al: Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood 1997; 89:2701-2705
40. Levi M, van der Poll, ten Cate H, et al: Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees. Am J Respir Crit Care Med 1998; 158:92-98
41. van der Poll T, de Jonge E, Levi M: Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27:639-651